Delivery Order SPE2DB22D9309-SPE2DB25FAF51
- Not listed
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $15,789.60 to DMS Pharmaceutical Group Inc. for Mitosol 0.2 mg kits. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform this delivery order at its facility in Park Ridge. The award was issued on May 12, 2025, with an ultimate completion date of June 3, 2025, and carries no set-aside designation. This delivery order falls under DMS...
- The Defense Logistics Agency awarded a $6,579.00 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. on September 26, 2025, for Mitosol 0.2 mg kits, with an ultimate completion date of October 20, 2025. This delivery order was issued without a set-aside designation and represents a continuation of the agency's ongoing pharmaceutical supply needs. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, serves as the prime...
- The Defense Logistics Agency (DLA) under the Medical Supply Chain issued a delivery order valued at $7,894.80 to DMS Pharmaceutical Group Inc. for Mitosol 0.2 mg kits. The award, made on August 1, 2025, with an ultimate completion date of August 22, 2025, represents a firm fixed-price delivery order with no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract (IDC) with the DLA valued at approximately $500 million through...
- The Defense Logistics Agency awarded a delivery order valued at $5,263.24 to DMS Pharmaceutical Group Inc. for Mitosol 0.2 mg kits, with an ultimate completion date of August 8, 2025. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was selected without a set-aside designation. The contract employs firm fixed-price pricing and represents a delivery order under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with...
- The Defense Logistics Agency awarded a $7,894.80 delivery order to DMS Pharmaceutical Group Inc. on September 23, 2025, for Mitosol 0.2 mg kits, with an ultimate completion date of October 15, 2025. This firm fixed-price delivery order was issued without a set-aside designation and is being performed in Park Ridge, Illinois. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, holds a significant single-award Indefinite Delivery Contract with...
- The U.S. Defense Logistics Agency (DLA) has awarded a firm fixed-price delivery order contract valued at $1,315.80 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the provision of Mitosol 0.2mg kits, a pharmaceutical product, with a period of performance through April 4, 2024. This delivery order is issued under DMS Pharmaceutical Group's existing indefinite delivery vehicle (IDV) contract 4600082013 with the DLA, valued at up...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $1,315.80 by the Defense Logistics Agency (DLA) on July 16, 2025, for the supply of Mitosol 0.2 mg kits. The contract employs firm fixed-price pricing with an ultimate completion date of August 6, 2025. This delivery order was issued without a set-aside designation, allowing DMS Pharmaceutical Group to compete on its merits as a certified...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Mitosol 0.2 mg kits. This firm fixed-price delivery order, valued at $1,315.80, was awarded on July 24, 2025, with an ultimate completion date of August 14, 2025. The contract carries no set-aside designation, allowing DMS Pharmaceutical Group to compete on an unrestricted basis in the federal procurement...
- The Defense Logistics Agency awarded a delivery order valued at $5,263.24 to DMS Pharmaceutical Group Inc. for Mitosol 0.2 mg kits, with an ultimate completion date of September 12, 2025. This firm fixed-price delivery order was issued without a set-aside designation to the woman-owned small business pharmaceutical wholesaler, which is based in Park Ridge, Illinois and will perform the work at that same location. DMS Pharmaceutical Group Inc. operates under a larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $6,579.00 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Mitosol 0.2 mg kits. This delivery order, issued on September 26, 2025, with an ultimate completion date of October 20, 2025, carries no set-aside designation. The award falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA valued at approximately...
- SPE2DB22D9309Indefinite Delivery Contract
- SPE2DB22D9309-SPE2DB25FAF51Delivery Order
The Defense Logistics Agency awarded a $1,315.80 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. for Mitosol 0.2 mg kits, with an ultimate completion date of October 8, 2025. DMS Pharmaceutical Group, a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was selected without a set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the DLA under the SPE2DB program, which has a $500 million ceiling and runs through November 2026, enabling the agency to procure a comprehensive range of pharmaceutical products and medical supplies for military health facilities. Mitosol is a mitomycin C preparation used in ophthalmic surgical procedures to prevent scarring and improve surgical outcomes. This delivery order reflects DMS Pharmaceutical Group's established role as a critical supplier within the federal pharmaceutical supply chain, supporting the Department of Defense's medical supply requirements. The company's contract portfolio demonstrates consistent success in securing federal pharmaceutical procurement through its woman-owned small business status and proven capability to deliver specialized medications and biologics to military healthcare systems nationwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.3k | 9/17/25 |